Allspring Global Investments Holdings LLC Acquires 25,105 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)

Allspring Global Investments Holdings LLC boosted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX) by 2,166.1% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 26,264 shares of the company’s stock after acquiring an additional 25,105 shares during the quarter. Allspring Global Investments Holdings LLC owned approximately 0.06% of Janux Therapeutics worth $282,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its position in shares of Janux Therapeutics by 10,740.0% in the fourth quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock valued at $29,000 after purchasing an additional 2,685 shares during the period. China Universal Asset Management Co. Ltd. bought a new position in shares of Janux Therapeutics in the fourth quarter valued at approximately $57,000. SG Americas Securities LLC bought a new position in shares of Janux Therapeutics in the fourth quarter valued at approximately $100,000. Old Well Partners LLC bought a new position in shares of Janux Therapeutics in the third quarter valued at approximately $104,000. Finally, Corton Capital Inc. bought a new position in shares of Janux Therapeutics in the third quarter valued at approximately $111,000. Institutional investors own 75.39% of the company’s stock.

Janux Therapeutics Price Performance

JANX opened at $47.39 on Friday. Janux Therapeutics, Inc. has a fifty-two week low of $5.65 and a fifty-two week high of $58.69. The firm’s fifty day moving average price is $39.14 and its two-hundred day moving average price is $19.49. The company has a market capitalization of $2.45 billion, a P/E ratio of -35.37 and a beta of 4.18.

Janux Therapeutics (NASDAQ:JANX) last posted its quarterly earnings results on Friday, March 8th. The company reported ($0.25) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The firm had revenue of $2.46 million for the quarter, compared to the consensus estimate of $0.98 million. On average, equities research analysts expect that Janux Therapeutics, Inc. will post -1.41 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on JANX shares. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, February 27th. Wedbush restated an “outperform” rating and issued a $53.00 price objective on shares of Janux Therapeutics in a research note on Monday, March 11th. BTIG Research began coverage on shares of Janux Therapeutics in a research note on Thursday, March 21st. They issued a “buy” rating and a $62.00 price objective on the stock. Cantor Fitzgerald began coverage on shares of Janux Therapeutics in a research note on Wednesday, March 20th. They issued an “overweight” rating and a $100.00 price objective on the stock. Finally, Bank of America raised their price objective on shares of Janux Therapeutics from $24.00 to $48.00 and gave the stock a “buy” rating in a research note on Wednesday, March 13th. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $61.33.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.